EP3609329A4 - Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors - Google Patents

Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors Download PDF

Info

Publication number
EP3609329A4
EP3609329A4 EP18783809.9A EP18783809A EP3609329A4 EP 3609329 A4 EP3609329 A4 EP 3609329A4 EP 18783809 A EP18783809 A EP 18783809A EP 3609329 A4 EP3609329 A4 EP 3609329A4
Authority
EP
European Patent Office
Prior art keywords
posaconazole
sensitization
compositions
methods
resistant tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18783809.9A
Other languages
German (de)
French (fr)
Other versions
EP3609329A1 (en
Inventor
Vikash J. BHAGWANDIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3609329A1 publication Critical patent/EP3609329A1/en
Publication of EP3609329A4 publication Critical patent/EP3609329A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
EP18783809.9A 2017-04-12 2018-04-12 Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors Withdrawn EP3609329A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762484852P 2017-04-12 2017-04-12
PCT/US2018/027371 WO2018191541A1 (en) 2017-04-12 2018-04-12 Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors

Publications (2)

Publication Number Publication Date
EP3609329A1 EP3609329A1 (en) 2020-02-19
EP3609329A4 true EP3609329A4 (en) 2021-03-17

Family

ID=63793667

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18783809.9A Withdrawn EP3609329A4 (en) 2017-04-12 2018-04-12 Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors

Country Status (6)

Country Link
EP (1) EP3609329A4 (en)
KR (1) KR20200059188A (en)
CN (1) CN111093373A (en)
AU (1) AU2018253189A1 (en)
CA (1) CA3063115A1 (en)
WO (1) WO2018191541A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037043A1 (en) * 2011-09-13 2013-03-21 Universite De Montreal Combination therapy using ribavirin as eif4e inhibitor
US20140315920A1 (en) * 2013-04-17 2014-10-23 Hedgepath, Llc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2016011328A1 (en) * 2014-07-17 2016-01-21 Baker Cheryl Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060291A1 (en) * 2004-05-28 2006-04-14 Schering Corp POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES
US20070281040A1 (en) * 2004-09-30 2007-12-06 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US8293754B2 (en) * 2005-06-14 2012-10-23 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
US8653083B2 (en) * 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
JP5205034B2 (en) * 2007-11-06 2013-06-05 ローム株式会社 Surface emitting laser diode
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037043A1 (en) * 2011-09-13 2013-03-21 Universite De Montreal Combination therapy using ribavirin as eif4e inhibitor
US20140315920A1 (en) * 2013-04-17 2014-10-23 Hedgepath, Llc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2016011328A1 (en) * 2014-07-17 2016-01-21 Baker Cheryl Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018191541A1 *

Also Published As

Publication number Publication date
CA3063115A1 (en) 2018-10-18
KR20200059188A (en) 2020-05-28
AU2018253189A1 (en) 2019-12-05
WO2018191541A1 (en) 2018-10-18
CN111093373A (en) 2020-05-01
EP3609329A1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
EP3642182A4 (en) Compounds, compositions and methods for synthesis
EP3436482A4 (en) Antibodies, pharmaceutical compositions and methods
EP3665156A4 (en) Compounds, compositions and methods
IL268620B2 (en) Anti-lag3 antibodies, pharmaceutical formulations comprising them and uses thereof for treating cancer
EP3891149A4 (en) Ret inhibitors, pharmaceutical compositions and uses thereof
HK1243999A1 (en) Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
EP3585433A4 (en) Therapeutic compositions and related methods for photoimmunotherapy
EP3676297A4 (en) Compounds, compositions and methods
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3491026A4 (en) Human antibodies, pharmaceutical compositions and methods
EP3466943A4 (en) Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof
EP3585426A4 (en) Compositions and methods for tumor transduction
EP3891148A4 (en) Ret inhibitors, pharmaceutical compositions and uses thereof
EP3369734A4 (en) Kinase inhibitor, and preparing method and pharmaceutical use thereof
EP3675860A4 (en) Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
HK1256674A1 (en) Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
EP3347348A4 (en) Preparation of 3-hydroxy-3,6-dimethylhexahydrobenzofuran-2-one and derivatives thereof
EP3877381A4 (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
EP3689857A4 (en) Griseofulvin compound and pharmaceutical use thereof
EP3670511A4 (en) Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition
EP3773654A4 (en) Polypharmaceutical drug compositions and related methods
EP3388433A4 (en) Phthalazine derivatives, and preparation method, pharmaceutical composition and use thereof
EP3638270A4 (en) Compositions and methods for enhancing hyperthermia therapy
EP3664797A4 (en) Nr4a1 ligands, pharmaceutical compositions, and related methods of use
EP3551613A4 (en) Compounds and pharmaceutical compositions for modulating sgk activity, and methods thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013994

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210211

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20210205BHEP

Ipc: A61K 31/475 20060101ALI20210205BHEP

Ipc: A61P 35/00 20060101ALI20210205BHEP

Ipc: A01N 43/48 20060101AFI20210205BHEP

Ipc: A61K 31/496 20060101ALI20210205BHEP

Ipc: A61K 31/337 20060101ALI20210205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231101